SecSonar.com

REGENXBIO Inc. (RGNX)

REGENXBIO Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

REGENXBIO Inc. (RGNX) is a Biotechnology company based in US with a market capitalization of $365.2M. Revenue grew 104.5% year-over-year and free cash flow was negative at -$126.4M. This page tracks RGNX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 353 employees · IPO Sep 17, 2015

Valuation

Valuation & price

$5.72 · as of May 17, 2026 · -64.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.56

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$15.08$10.37$5.65Jul 25Dec 25Jul 26Jul 7, 25$8.43Jul 9, 25$9.17Jul 11, 25$8.68Jul 15, 25$8.24Jul 17, 25$8.69Jul 21, 25$8.49Jul 23, 25$9.09Jul 25, 25$8.96Jul 29, 25$8.41Jul 31, 25$8.51Aug 4, 25$8.33Aug 6, 25$8.23Aug 11, 25$7.46Aug 13, 25$8.93Aug 15, 25$8.82Aug 19, 25$8.03Aug 21, 25$8.11Aug 25, 25$8.97Aug 27, 25$8.82Aug 29, 25$8.93Sep 3, 25$9.86Sep 5, 25$9.71Sep 9, 25$9.89Sep 11, 25$9.49Sep 16, 25$9.26Sep 18, 25$9.36Sep 22, 25$9.06Sep 24, 25$9.54Sep 26, 25$9.65Sep 30, 25$9.65Oct 2, 25$10.58Oct 6, 25$10.69Oct 8, 25$12.22Oct 10, 25$10.92Oct 14, 25$11.25Oct 16, 25$12.34Oct 21, 25$13.09Oct 23, 25$12.58Oct 27, 25$13.62Oct 29, 25$12.84Oct 31, 25$12.77Nov 4, 25$11.56Nov 6, 25$11.17Nov 10, 25$11.02Nov 12, 25$11.60Nov 14, 25$11.51Nov 18, 25$11.25Nov 20, 25$10.87Nov 25, 25$13.45Nov 28, 25$13.39Dec 2, 25$12.21Dec 4, 25$12.98Dec 8, 25$13.24Dec 10, 25$13.06Dec 12, 25$13.87Dec 16, 25$14.11Dec 18, 25$13.51Dec 22, 25$14.97Dec 24, 25$14.46Dec 29, 25$14.30Jan 2, 26$13.57Jan 6, 26$14.18Jan 8, 26$15.00Jan 12, 26$15.08Jan 14, 26$14.95Jan 16, 26$13.62Jan 21, 26$15.02Jan 23, 26$13.79Jan 27, 26$13.41Jan 29, 26$11.60Feb 2, 26$10.78Feb 4, 26$10.75Feb 9, 26$10.31Feb 11, 26$8.50Feb 13, 26$7.99Feb 18, 26$7.90Feb 20, 26$8.14Feb 24, 26$8.08Feb 26, 26$8.75Mar 2, 26$9.24Mar 4, 26$9.14Mar 6, 26$8.65Mar 10, 26$9.90Mar 12, 26$9.08Mar 17, 26$8.64Mar 19, 26$8.36Mar 23, 26$8.34Mar 25, 26$8.46Mar 27, 26$7.76Mar 31, 26$8.38Apr 2, 26$8.53Apr 7, 26$8.80Apr 9, 26$8.96Apr 13, 26$9.04Apr 15, 26$9.36Apr 17, 26$9.49Apr 22, 26$9.34Apr 24, 26$8.76Apr 28, 26$8.69Apr 30, 26$8.97May 4, 26$9.39May 6, 26$10.22May 8, 26$10.55May 12, 26$10.24May 14, 26$6.25May 18, 26$5.65May 20, 26$5.97May 22, 26$6.35May 28, 26$6.89Jun 1, 26$7.14Jun 3, 26$6.69Jun 5, 26$6.08Jun 9, 26$6.34Jun 11, 26$6.28Jun 15, 26$7.07Jun 17, 26$7.90Jun 22, 26$9.07Jun 24, 26$9.97Jun 26, 26$10.48Jul 2, 26$13.28
$5.6552-week range$15.98
Loading valuation history…

Fundamentals

Key fundamentals

$365.2M

Market cap

104.5%

Revenue growth (YoY)

88.1%

Gross margin

-$126.4M

Free cash flow (USD)

$30.4M

Net debt

4.2%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$4.6MFY 2017$10.4MFY 2018$218.5MFY 2019$35.2MFY 2020$154.6MFY 2021$470.3MFY 2022$112.7MFY 2023$90.2MFY 2024$83.3MFY 2025$170.4M
$4.6M$170.4M

Free cash flow by year

2016 → 2025

FY 2016$-56.7MFY 2017$-65.2MFY 2018$91.4MFY 2019$-119.4MFY 2020$-80.9MFY 2021$134.7MFY 2022$-238.2MFY 2023$-228.4MFY 2024$-175.6MFY 2025$-126.4M
-$56.7M-$126.4M

Gross margin by year

2021 → 2025

FY 202189.0%FY 202251.6%FY 202358.8%FY 202459.7%FY 202588.1%
89.0%88.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last reported: May 14, 2026 (EPS $-1.72)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $689K · 10b5-1 PlanPAKOLA STEVE · Chief Medical Officer · $688.8KJul 1, 2026Filing
  • 8-K eventMilestone Payment ReceivedJun 29, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 3, 2026Filing
  • 8-K eventEarnings ReleaseMay 14, 2026Filing
  • Quarterly report10-Q FiledMay 14, 2026Filing
  • Insider sellInsider Sell $169K · 10b5-1 PlanPAKOLA STEVE · Chief Medical Officer · $168.7KMay 13, 2026Filing

Questions

Frequently asked questions

What is REGENXBIO Inc.'s market cap?

REGENXBIO Inc. (RGNX) has a market capitalization of $365.2M.

What is RGNX's P/E ratio?

A meaningful P/E ratio is not available for RGNX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is RGNX's price-to-book (P/B) ratio?

RGNX trades at 3.56 times book value per share.

When did REGENXBIO Inc. last report earnings?

RGNX last reported earnings on May 14, 2026; the next date is not yet scheduled.

Are insiders buying RGNX stock?

SEC Form 4 filings show no open-market insider buys at REGENXBIO Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

PBYI

Puma Biotechnology, Inc.

$364.7M

IRD

Opus Genetics, Inc.

$364.7M

PALI

Palisade Bio, Inc.

$366.3M

CCCC

C4 Therapeutics, Inc.

$367.8M

PTN

Palatin Technologies, Inc.

$368M

KROS

Keros Therapeutics, Inc.

$361.9M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.